CERo Therapeutics Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CERO research report →
Price Chart
About the company
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors.
- CEO
- Christopher Ehrlich
- IPO
- 2021
- Employees
- 8
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on CERO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $406.01K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -0.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 131.14%
- ROIC
- 79.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,086,034+6.6%
- Op Income
- $-18,463,149
- Net Income
- $-19,920,262-157.6%
- EPS
- $-22.58-228.7%
- OCF Growth
- -177.7%
- FCF Growth
- -177.7%
- 52W High
- $5.66
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.03
- Beta
- 0.16
- RSI (14)
- 41
- Avg Volume
- 602.57K
No earnings-call transcripts are available for CERO yet.
- Free Float
- 95.9%
- Shares Outstanding
- 45.11M
- Float Shares
- 43.25M
of shares held by institutions
8 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 26 | Francois Eric | other | 1,823,278 |
| Feb 13, 26 | Francois Eric | other | 0 |
| Jan 7, 26 | Rolfe Lindsey | other | 690,900 |
| Jan 7, 26 | LAPORTE KATHLEEN | other | 690,900 |
| Jan 7, 26 | Pierce Kristen | other | 1,612,099 |
| Jan 7, 26 | Patel Shami | other | 690,900 |
| Jan 7, 26 | ATWOOD BRIAN G | other | 1,612,099 |
| Jan 7, 26 | Ehrlich Christopher B | other | 4,530,997 |
| Jan 7, 26 | Byrnes Michael | other | 690,900 |
| Jan 7, 26 | KUCHARCHUK ANDREW ALBERT | other | 1,162,099 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CERO coverage
Recent articles, reports, and earnings notes.
No research on CERO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CERO report →CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
globenewswire.com · Jun 15
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
globenewswire.com · Jun 15
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
globenewswire.com · May 11
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
globenewswire.com · May 11
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
globenewswire.com · Apr 14
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
globenewswire.com · Mar 30
CERo Therapeutics Provides Shareholder Update
globenewswire.com · Mar 11
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
globenewswire.com · Feb 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.